OST RESPONSES TO ERTUGLIFLOZIN


ETHICS STATEMENT The retrospective study design was submitted to both Murdoch University and the University of Western Australia. In line with their protocols, neither committee considered that ethical approval was necessary as the data collection was retrospective from clinical cases.


ORCID Tania Sundra https://orcid.org/0000-0003-0556-4406 David Rendle https://orcid.org/0000-0001-6943-6425


REFERENCES


Bays , H. ( 2013 ) Sodium glucose co-transporter type 2 (SGLT2) inhibitors: targeting the kidney to improve glycemic control in diabetes melli- tus . Diabetes Therapy , 4 ( 2 ), 195 – 220 .


Bertin , F.R. & de Laat , M.A. ( 2017 ) The diagnosis of equine insulin dys- regulation . Equine Veterinary Journal , 49 , 570 – 576 .


Bröjer , J. , Svonni , E. & Lindase , S. ( 2023 ) Short-term effects of canagliflozin on β-cell function in horses with insulin dysregulation – preliminary results from an ongoing randomized, double-blind, placebo-controlled trial . In: 5th global equine endocrine symposium 2023, Bern, Switzerland .


Choi , M.-K. , Nam , S.J. , Ji , H.-Y. , Park , M.J. , Choi , J.-S. & Song , I.-S. ( 2020 ) Comparative pharmacokinetics and pharmacodynamics of a novel sodium-glucose cotransporter 2 inhibitor, DWP16001, with da- pagliflozin and ipragliflozin . Pharmaceutics , 12 , 268 .


de Laat , M.A. , McGree , J.M. & Sillence , M.N. ( 2016 ) Equine hyperin- sulinemia: investigation of


the enteroinsular axis during insulin


dysregulation . American Journal of Physiology – Endocrinology and Metabolism , 310 , E61 – E72 .


de Laat , M.A. & Sillence , M.N. ( 2020 ) A review of recent developments in the pharmacological prevention and treatment of endocrinopathic laminitis . Animal Production Science , 60 , 2111 .


Dunkel , B. , Wilford , S.A. , Parkinson , N.J. , Ward , C. , Smith , P. , Grahame , L. et al. ( 2013 ) Severe hypertriglyceridaemia in horses and ponies with endocrine disorders: Hypertriglyceridaemia in horses with en- docrine disorders . Equine Veterinary Journal , 46 , 118 – 122 .


Durham , A.E. , Frank , N. , McGowan , C.M. , Menzies-Gow , N.J. , Roelfsema , E. , Vervuert , I. et al. ( 2019 ) ECEIM consensus statement on equine metabolic syndrome . Journal of Veterinary Internal Medicine , 33 , 335 – 349 .


Fediuk , D.J. , Nucci , G. , Dawra , V.K. , Cutler , D.L. , Amin , N.B. , Terra , S.G. et al. ( 2020 ) Overview of the clinical pharmacology of ertugliflozin, a novel sodium-glucose cotransporter 2 (SGLT2) inhibitor . Clinical Pharmacokinetics , 59 , 949 – 965 .


Ferrannini , E. , Baldi , S. , Frascerra , S. , Astiarraga , B. , Heise , T. , Bizzotto , R. et al. ( 2016 ) Shift to fatty substrate utilization in response to so- dium–glucose cotransporter 2 inhibition in subjects without diabe- tes and patients with type 2 . Diabetes , 65 , 1190 – 1195 .


Ferrannini , E. , Muscelli , E. , Frascerra , S. , Baldi , S. , Mari , A. , Heise , T. et al. ( 2014 ) Metabolic response to sodium-glucose cotransporter 2 in- hibition in type 2 diabetic patients . Journal of Clinical Investigation , 124 , 499 – 508 .


Frank , N. ( 2018 ) Safety and efficacy of canagliflozin and octreotide for managing insulin dysregulation in horses . In: 2018 ACVIM forum re- search abstract program, Seattle, Washington . pp. 2123–2143.


Frank , N. , Bailey , S. , Bertin , F.-R. , Burns , T. , de Laat , M. , Durham , A. et al. ( 2022 ) Recommendations for the diagnosis and management of equine metabolic syndrome . Equine Endocrinology Group . Available from: https:// sites. tufts. edu/ equin eendo group/ files/ 2022/ 10/ EMS- EEG- Recom menda tions- 2022. pdf


Frank , N. & Tadros , E.M. ( 2013 ) Insulin dysregulation: insulin dysregula- tion . Equine Veterinary Journal , 46 , 103 – 112 .


Frank , N. , Thane , K. , Voth , R. , Klee , R. & Warnken , T. ( 2023 ) The sodi- um-glucose cotransporter-2 inhibitor velagliflozin decreases basal


| 323


plasma insulin concentrations in horses with moderate-severe insulin dysregulation . In: Proceedings of the American College of Veterinary Internal Medicine 2023, Seattle, USA . p. 2129.


Henneke , D.R. , Potter , G.D. , Kreider , J.L. & Yeates , B.F. ( 1983 ) Relationship between condition score, physical measurements and body fat per- centage in mares . Equine Veterinary Journal , 15 , 371 – 372 .


Janež , A. & Fioretto , P. ( 2021 ) SGLT2 inhibitors and the clinical implica- tions of associated weight loss in type 2 diabetes: a narrative re- view . Diabetes Therapy , 12 , 1 – 13 .


Jocelyn , N.A. , Harris , P.A. & Menzies-Gow , N.J. ( 2018 ) Effect of varying the dose of corn syrup on the insulin and glucose response to the oral sugar test . Equine Veterinary Journal , 50 , 836 – 841 .


Kalra , S. ( 2014 ) Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology . Diabetes Therapy , 5 , 355 – 366 .


Kalra , S. , Singh , V. & Nagrale , D. ( 2016 ) Sodium-glucose cotransporter-2 inhibition and the glomerulus: a review . Advances in Therapy , 33 , 1502 – 1518 .


Kellon , E.M. & Gustafson , K.M. ( 2022 ) Use of the SGLT2 inhibitor cana- gliflozin for control of refractory equine hyperinsulinemia and lam- initis . Open Veterinary Journal , 12 , 511 – 518 .


Li , Y. , Mu , Y. , Shi , H. , Liang , Y. , Liu , Z. , Matschke , K. et al. ( 2020 )


Pharmacokinetic properties of single and multiple doses of ertug- liflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects . Clinical Pharmacology in Drug Development , 9 , 97 – 106 .


Li , Y. , Nucci , G. , Yamamoto , Y. , Fediuk , D.J. & Sahasrabudhe , V. ( 2021 ) Pharmacokinetics


and pharmacodynamics of ertugliflozin in


healthy Japanese and Western subjects . Clinical Pharmacology in Drug Development , 10 , 765 – 776 .


Macon , E.L. , Harris , P. , Partridge , E. , Barker , V.D. & Adams , A. ( 2021 ) Effect of dose and fasting on oral sugar test responses in insulin dysregu- lated horses . Journal of Equine Veterinary Science , 107 , 103770 .


Meier , A. , McGree , J. , Klee , R. , Preuß , J. , Reiche , D. , de Laat , M. et al. ( 2021 ) The application of a new laminitis scoring method to model the rate and pattern of improvement from equine endocrinopathic laminitis in a clinical setting . BMC Veterinary Research , 17 , 16 .


Meier , A. , Reiche , D. , de Laat , M. , Pollitt , C. , Walsh , D. & Sillence , M. ( 2018 ) The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregu- lated ponies . PLoS One , 13 , e0203655 .


Meier , A. , de Laat , M. , Reiche , D. , Fitzgerald , D. & Sillence , M. ( 2019 ) The efficacy and safety of velagliflozin over 16 weeks as a treatment for insulin dysregulation in ponies . BMC Veterinary Research , 15 , 65 .


Nauck , M.A. ( 2014 ) Update on developments with SGLT2 inhibitors in the management of type 2 diabetes . Drug Design, Development and Therapy , 8 , 1335 – 1380 .


Sargent , J. ( 2015 ) SGLT2 inhibitor dapagliflozin promotes glucagon se- cretion in [alpha] islet cells . Nature Reviews Endocrinology , 11 , 382 .


Schuver , A. , Frank , N. , Chameroy , K.A. & Elliott , S.B. ( 2014 ) Assessment of insulin and glucose dynamics by using an Oral sugar test in horses . Journal of Equine Veterinary Science , 34 , 465 – 470 .


Sha , S. , Devineni , D. , Ghosh , A. , Polidori , D. , Chien , S. , Wexler , D. et al. ( 2011 ) Canagliflozin, a novel inhibitor of sodium glucose co-trans- porter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects . Diabetes Obesity and Metabolism , 13 , 669 – 672 .


Suagee , J.K. , Corl , B.A. , Hulver , M.W. , McCutcheon , L.J. & Geor , R.J. ( 2011 ) Effects of hyperinsulinemia on glucose and lipid trans- porter expression in


insulin-sensitive horses . Domestic Animal Endocrinology , 40 , 173 – 181 .


Sundra , T. , Kelty , E. & Rendle , D. ( 2023 ) Preliminary observations on the use of ertugliflozin in the management of hyperinsulinaemia and laminitis in 51 horses: a case series . Equine Veterinary Education , 35 , 311 – 320 .


Suzuki , Y. , Kaneko , H. , Okada , A. , Itoh , H. , Matsuoka , S. , Fujiu , K. et al. ( 2022 ) Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus . Cardiovascular Diabetology , 21 , 67 .


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88